Omeros Corporation
OMERHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 27
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The $801.2M market capitalization puts OMER squarely in small-cap range for its industry. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Market Cap
$801.2M
Beta
2.66
P/E (TTM)
9.71
P/E (Fwd)
20.50
EPS (TTM)
$1.14
EPS (Fwd)
$0.54
ROE
—
ROA
-25.2%
Cash
$135.3M
Total Debt
$226.6M
Free CF
$181.0M
52W Change
233.4%
Annual Financials
Cash vs Debt
Omeros Corporation carries $226.6M in total debt against $135.3M in cash reserves — debt is roughly 1.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $181.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health.
A beta of 2.66 means OMER is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Omeros Corporation and its sector.